Protein therapeutics are playing an increasingly important role in treatment of a variety of
human diseases. However, like the rest of proteins, they are susceptible to aggregation. Aggregation
of proteinaceous pharmaceuticals can cause a loss of efficacy and, potentially, cytotoxicity and an
immunogenic response. This review describes various ways protein therapeutics aggregate and a
variety of approaches taken to prevent or minimize this process.
Keywords: Aggregation, formulation, storage, delivery, insulin, glucagon, antibodies
Rights & PermissionsPrintExport